Q3 2026's Biggest Health & Biotech Funding Rounds: Chai Discovery's $400M Leads 9 Tracked Deals

Chai Discovery's $400 million Series C, led by Index Ventures, was the biggest health and biotech funding round Value Add VC had tracked for Q3 2026 as of October 15, 2026 — leading a group of 53 tracked rounds worth $5.02 billion combined.

These are rounds tracked by Value Add VC for US and unconfirmed-HQ private companies, as of October 15, 2026; rumored rounds, public-company raises, and known non-US companies are excluded. This is not a health and biotech market total — it's a slice of the market from the sources Value Add VC follows, meant to be compared quarter to quarter within this series rather than against PitchBook, Crunchbase, or other trackers' totals. Below are 9 of the biggest rounds, ranked, each linked to its own source.

Biggest Health & Biotech Funding Rounds Q3 2026: The Full List, Ranked by Size

Tracked as of October 15, 2026, Chai Discovery's $400 million Series C tops the list, followed by Catalio Capital Management-led Enveda Biosciences' $311 million Series E and ByteDance spinout Anew Labs' $290 million round. Two of the three biggest rounds — Chai Discovery and Anew Labs — went to companies building AI models for drug discovery, continuing the AI-in-biotech theme tracked across Value Add VC's funding coverage.

Computed from the Value Add VC intelligence store on 2026-10-15: health and biotech funding rounds of US and unconfirmed-HQ private companies announced in Q3 2026; rumored rounds, public-company raises, and known non-US companies excluded; one record per deal. Not a market total; each company name links its own source. How we counted: rounds Value Add VC's intelligence store had on file for Q3 2026; ranked by disclosed round size; 9 of 53 tracked deals; as of October 15, 2026.

What Was the Biggest Health and Biotech Funding Round in Q3 2026?

Chai Discovery's $400 million Series C, led by Index Ventures and reported by Law360 on July 14, 2026, was the largest health and biotech round Value Add VC tracked for the quarter, valuing the AI drug-discovery company at $3.8 billion.

The next two rounds landed within a week of each other in September: Enveda Biosciences' $311 million Series E, led by Catalio Capital Management and announced September 23, 2026 at a roughly $2 billion valuation, and ByteDance spinout Anew Labs' $290 million round, reported September 16, 2026 at a $1.5 billion valuation and co-led by HongShan (formerly Sequoia China), IDG Capital, and Hillhouse Investment.

Why Did AI Drug-Discovery Startups Raise the Biggest Checks in Q3 2026?

Two of the three biggest Q3 2026 health and biotech rounds Value Add VC tracked went to companies applying AI models to drug discovery rather than traditional clinical-stage biotechs: Chai Discovery, whose $3.8 billion valuation makes it one of the highest-valued AI-drug-discovery startups tracked this quarter, and Anew Labs, the drug-discovery unit ByteDance spun off with backing from HongShan, IDG Capital, and Hillhouse. AI-native clinical products also drew large checks: OpenEvidence's $250 million round, led by Andreessen Horowitz and reported September 25, 2026, and Scan.com's $220 million raise, led by Noteus to build what the company calls the largest medical-imaging network in the US.

Not every round in the top 9 named a clear single lead or disclosed stage. Fortell's $163 million round, backed by Founders Fund, Thrive Capital, and Valor Equity Partners, valued the AI hearing-aid startup at $740 million but wasn't reported with a named series. Celea Therapeutics' $180 million financing and Anew Labs' $290 million round were also reported without a stated stage.

How We Built This List

This ranking covers US and unconfirmed-HQ-private-company health and biotech funding rounds in the Value Add VC intelligence store that were announced in Q3 2026 (July-September), with one record kept per deal. It excludes rumored rounds, public-company capital raises, and companies with a confirmed non-US headquarters. The store tracked 53 such rounds worth $5.02 billion combined as of October 15, 2026 — a slice of the market from the sources Value Add VC follows, not a claim to cover every health and biotech round that closed in the quarter.

Every row above is checked against its own linked source. One round the store had on file, Rightway's $155 million Series E, was dropped from this list because the lead investor's own press release dated the deal to September 24, 2026, a day earlier than the store's internal record, so it is left out rather than published with a disputed date. Precision Neuroscience's $250 million Series D and Scan.com's $220 million Series C are both cited to the outlets that first reported them, GlobeNewswire and Fierce Healthcare, after both pages returned a paywall or access block when checked for this list.

Value Add VC also publishes hand-reconciled Q3 2026 venture-funding figures, where dates and lead investors are corrected after additional review; those figures can differ slightly from this list's as-tracked totals. The full round-level log this list draws from is public at Value Add VC's funding tracker.

What the headline misses

A ranked list by round size flattens very different kinds of disclosure quality into one table. Four of the 9 rows above — Enveda Biosciences, Anew Labs, Encoded Therapeutics, and Scan.com — carry no official company page on Value Add VC and are sourced entirely to outside reporting rather than a filing or company press release in every case. Two rows, Precision Neuroscience and Scan.com, could not be independently re-verified for this list because their original sources returned access blocks, so their figures rest on the Value Add VC store's internal record rather than a fresh check. Treat "9 biggest rounds" as a size ranking built from the best available sourcing, not a claim that every figure carries equal certainty.